Sol-Gel Technologies Ltd (SLGL)

Etorro trading 970x250

About Sol-Gel Technologies Ltd

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Address: 7 Golda Meir Street, Ness Ziona, Israel, 7403650

Sol-Gel Technologies Ltd News and around…

Latest news about Sol-Gel Technologies Ltd (SLGL) common stock and company :

The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
11 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus MerckCommences ...

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
11 Nov, 2021 Yahoo! Finance

Sol-Gel attains a profitable quarter, reporting total revenues of $8.8 million, net income of $1.3 million and EPS of $0.06Recently obtained FDA approval of TWYNEO® triggers a $3.5 million milestone payment from Galderma, and, together with the $4.0 million down payment from Galderma, a total of $7.5 million was recognized in Q3Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs based on a ne

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
09 Nov, 2021 Yahoo! Finance

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Jefferies London Healthcare Conference, taking place in-person on November 16th and 17th, 2021. Jefferies London Healthcare Conference Presentation Information:FormatLive presentation and 1-o

Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
04 Nov, 2021 Yahoo! Finance

- Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs - Sol-Gel to retain two generic programs encompassing four high-value generic drug candidates - Sol-Gel’s cash runway expected to extend through at least Q4 2023 - Sol-Gel’s focus remains on supporting Galderma to launch TWYNEO®, and EPSOLAY®, subject to its FDA approval, along with advancing its innovative pipeline of assets NESS ZIONA, I

Analysts See 28% Upside For The Holdings of RYJ
02 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $82.32 per unit.

Will Sol-Gel Technologies (NASDAQ:SLGL) Spend Its Cash Wisely?
01 Oct, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysts Predict 28% Gains Ahead For RYJ
23 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $76.63 per unit.

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
22 Sep, 2021 FinancialContent
Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
09 Sep, 2021 FinancialContent
What Is The Ownership Structure Like For Sol-Gel Technologies Ltd. (NASDAQ:SLGL)?
17 Aug, 2021 Yahoo! Finance

The big shareholder groups in Sol-Gel Technologies Ltd. ( NASDAQ:SLGL ) have power over the company. Large companies...

Implied RYJ Analyst Target Price: $76
10 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $75.59 per unit.

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
04 Aug, 2021 FinancialContent
Earnings Scheduled For August 4, 2021
04 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second ...

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris
27 Jul, 2021 FinancialContent

TheFDA has approvedSol-Gel Technologies Ltd's(NASDAQ: SLGL) first proprietary drug product, Twyneo ...

Sol-Gel Technologies Announces FDA Approval of TWYNEO®
27 Jul, 2021 FinancialContent
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
20 Jul, 2021 FinancialContent
Sol-Gel Announces Pipeline Update and Future Development Plans
28 Jun, 2021 FinancialContent
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
28 Jun, 2021 FinancialContent

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.

Analysts Anticipate RYJ Will Reach $73
04 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $72.67 per unit.

Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
27 May, 2021 FinancialContent
Does Sol-Gel Technologies' (NASDAQ:SLGL) Share Price Gain of 23% Match Its Business Performance?
18 May, 2021 Yahoo! Finance

The Sol-Gel Technologies Ltd. ( NASDAQ:SLGL ) share price is down a rather concerning 30% in the last month. Taking a...

74 Biggest Movers From Friday
17 May, 2021 FinancialContent

Gainers MoSys, Inc. (NASDAQ: MOSY) shares climbed 50.5% to settle at $4.35 on Friday. MoSys, last week, reported a loss for its ...

77 Biggest Movers From Yesterday
14 May, 2021 FinancialContent

Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped ...

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
13 May, 2021 FinancialContent
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
01 May, 2021 FinancialContent

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA ...

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
01 May, 2021 FinancialContent

Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA ...

Sol-Gel Technologies Becomes Oversold (SLGL)
30 Apr, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL
29 Apr, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sol-Gel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining ...

52 Biggest Movers From Yesterday
28 Apr, 2021 FinancialContent

Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) gained 51.2% to close at $24.90 on Tuesday. Urban Tea, Inc. (NASDAQ: MYT) ...

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sol-Gel Technologies Ltd. (SLGL) Investigation
27 Apr, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / April 27, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sol-Gel Technologies Ltd. ("Sol-Gel" or "the Company") (NASDAQ:SLGL).

Sol-Gel Technologies Ltd (SLGL) is a NASDAQ Common Stock listed in , ,

970x250